Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“I couldn’t be more pleased with Bill Beyer’s contributions to Tubi as interim CFO during the hypergrowth stage of the company. His experienced management acumen, strategic insights, financial expertise allowed us to be super-selective in our CFO search. He owned a tremendous debt financing providing Tubi with great optionality for further financings as well as the necessary resources to fund our growth. I wouldn’t hesitate to bring Bill and FLG in again on Tubi’s behalf.”